证券代码：300819 证券简称：聚杰微纤 江苏聚杰微纤科技集团股份有限公司 问题八：2024年的利润分配预案为每 10 股派发现金红利 3 元，公司制定这一预案的依据是什么？是否考虑了公司未来 的发展资金需求？ 答：尊敬的投资者， 您好！公司在确保满足未来业务发展 资金需求的基础上，制定科学合理的利润分配政策。我们致力于 平衡企业长远发展与投资者回报，通过稳定的分红政策与全体股 东共享经营成果。 问题九：高管您好，请问贵公司未来盈利增长的主要驱动 因素有哪些？谢谢。 投资者关系活动记录表 编号：2025-009 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 □新闻发布会 □现场参观 ☑ 业绩说明会 □路演活动 □其他 (请文字说明其他活动内容) 参与单位名称及 人员姓名 通过价值在线参与公司 2024 年度网上业绩说明会的投资者 时间 2025 年 4 月 23 日 15:00-17:00 地点 价值在线（www.ir-online.cn） 上市公司接待人 员姓名 董事长兼总裁：仲鸿天 董事兼副总裁：沈松 董事会秘书兼副总裁：黄亚辉 财务总监：程晓军 独立董事：尤敏卫 投资者关系活动 主要 ...

投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 活动参与人员 被接待人员：社会公众投资者等 公司接待人员： 董事长、总经理费振勇先生 副总经理、财务负责人马志刚先生 独立董事郜卓先生 董事会秘书王潇先生 时间 2025 年 4 月 23 日 地点 全景网"投资者关系互动平台" 形式 网络远程 交流内容及具 体问答记录 1、报告期内公司盈利水平如何？ 回复：尊敬的投资者，您好，2024年公司实现营业收入46.36亿元，同比增 长9.29%；归属上市公司股东净利润3.12亿元，感谢您的关注。 2、报告期内行业整体情况如何？公司相较于其他公司表现如何？ 回复：尊敬的投资者，您好，感谢对公司的关注。2024年公司实现营业收 入46.36亿元，同比增长9.29%；归属上市公司股东净利润3.12亿元。公司收入规 模稳步上升，在金融IT行业中处于前列。 3、公司未来的盈利增长点有哪些？ 回复：尊敬的投资者，您好，感谢对公司的关注。随着大模型技术不断迭 代发展，金融机构将持续加大在"AI+金融"领域的资源投入与产业化应用探索， AI技术在该领域从局部试点向多维度应用 ...

广东蒙泰高新纤维股份有限公司 投资者关系活动记录表 编号：2025-003 答:尊敬的投资者您好,截至2025年4月3日披露的 2024年年报，控股孙公司广东纳塔手续方面完成了项目 第二批用地的招拍手续，取得用地规划许可等证件；现 场完成详勘等工程，桩基础和围墙完工，办公楼等已开 工建设。控股孙公司甘肃纳塔已取得多项许可证及完成 图纸审查等工作；项目一期已实现综合楼主体施工过 半，碳化车间完成基础建设，钢结构工程进入收尾阶 段。目前两地的工程进展正在有条不紊地推进。 感谢您 对公司的关注。 3.财务费用大幅增长的原因 答:尊敬的投资者您好,2024年财务费用大幅增长主 要是报告期可转债费用化利息增加所致；2024年上半年 财务费用大幅增加主要是报告期银行定期存款产品减少 导致利息收入减少，以及银行贷款的增加导致利息支出 增加引起。 感谢您对公司的关注。 4.领导如何看行业后续的发展？公司未来的重心会 放在哪？ 答:尊敬的投资者您好，2025年国际格局深刻调整， 全球经济不确定、贸易环境复杂，但化纤行业有全产业 链优势，坚持科技创新等能推动可持续发展。公司未来 重心，一是聚焦丙纶长丝主业，利用新增产能提升份 额 ...

Group 1: Company Performance - The overall gross margin for 2024 is 39.65%, a slight decrease of 0.73% compared to the previous year, primarily due to intensified competition [2] - The company has maintained a growth trend in profitability over recent years, indicating sustainability [2] Group 2: Research and Development - The R&D investment intensity has consistently remained above 8% of operating revenue over the past three years [3] - As of the end of 2024, the company holds 358 software copyrights, 79 effective patents (including 45 invention patents and 34 utility model patents), and 266 safety standard product certifications [3] Group 3: Cash Flow and Customer Relations - Significant improvement in cash flow is attributed to increased operating cash flow due to performance growth, good payment willingness from downstream customers, and enhanced management and sales team capabilities [3] Group 4: Strategic Focus and Market Position - The company aims to focus on the mining sector, providing technological services and comprehensive solutions for intelligent construction and machine replacement strategies [2] - The company is actively expanding its smart mining business, with a positive order situation [3] Group 5: Supply Chain and International Expansion - The company has minimal reliance on external chip procurement, which mitigates the impact of tariffs on the supply chain [3] - International business expansion is primarily supported through key clients' international strategies, such as Zijin Mining [3]

Group 1: Market Competition and Product Strategy - The domestic allergy treatment market growth has slowed to 8%, with competitors like Novartis and ALK accelerating sublingual desensitization therapy [1] - The company has three dust mite desensitization drugs approved for nationwide sale, including its own "Dust Mite Drops" [1] - The company is not concerned about competition, believing that more participants can help expand the market [1] Group 2: Cost Structure and Financial Management - The company's main product costs remained stable in 2024, with a high gross margin [2] - Future cost optimization will focus on external procurement and production planning, although the potential for significant cost reduction is limited due to high margins [2] - The company has entrusted financial management with an amount of 206.5 million yuan, with an unexpired balance of 194.838 million yuan [2] Group 3: Research and Development Focus - The company is developing new major medical products, including stem cell therapies and natural drugs (anti-drug-resistant antibiotics) [2][4] - Current R&D investments are primarily focused on allergen products, with plans to enter new medical fields [4] - New drug development cycles are long and risky, making it difficult to predict product launch timelines [4] Group 4: Industry Standards and Regulatory Compliance - The company has established its own drug registration standards, which have been approved by the National Medical Products Administration [4] - Participation in industry standard formulation enhances the company's influence and competitiveness in the allergy treatment sector [4]

Financial Performance - In 2024, the company achieved a revenue of 3.235 billion CNY, a year-on-year increase of approximately 8.57% [10] - The net profit attributable to shareholders reached 188 million CNY, with a significant increase of 842.28% year-on-year [3][5] - The overall gross margin improved to 32.92%, an increase of 6.12 percentage points compared to the previous year [5] Revenue Structure - The main revenue source was the proprietary software business, generating 1.774 billion CNY, with a year-on-year growth of 16.17% [4] - Traditional business remained stable, aligning with the company's strategic layout for 2024 [4] Cash Flow and Profitability - The company focused on profit and cash flow as core operational goals, achieving a substantial improvement in cash flow [5] - Sales expenses decreased by nearly 19.3%, reflecting effective cost control measures [5] AI Business Development - AI-related business generated approximately 78 million CNY in 2024, marking significant growth compared to 2023 [5] - In Q1 2025, AI projects achieved revenue of about 33 million CNY, with a notable increase in business opportunities [8][10] Market Trends and Strategic Focus - The company is transitioning from service-based to product-based business models, aiming to enhance profitability and market competitiveness [16] - The focus on AI and PaaS platforms is expected to drive future revenue growth, with a strategic shift towards these areas [9][12] Customer Engagement and Retention - Over 90% of AI-related revenue comes from existing customers, highlighting strong customer loyalty and trust [15] - The company plans to leverage its established relationships to promote new AI offerings effectively [15] Future Outlook - The company anticipates that by 2027, AI will become a primary revenue driver, surpassing traditional digital transformation solutions [12] - Continuous investment in R&D and market expansion is planned to maintain competitive advantage in the evolving AI landscape [19][20]

证券代码：301511 证券简称：德福科技 九江德福科技股份有限公司 投资者关系活动记录表 编号：2025-002 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 具体名单见附件 | | 时间 | 2025年4月21日 16:00-17:00 | | 地点 | 电话会议 | | 上市公司接待人员姓名 | 副总经理、董事会秘书 吴丹妮女士 | | | 投资者关系经理 左净霭女士 一、公司经营情况介绍 | | | 公司于 2025 年 4 月 19 日发布 2024 年年度报告和 2025 年一季 | | 投资者关系活动主要内容 | 度报告。2024 年公司实现营业收入 78.05 亿元，同比增加 | | | 19.51%；归属于上市公司股东的净利润为-2.45 亿元，同比下降 | | 介绍 | 284.56%；归属于上市公司股东的扣非净利润为-2.36 亿元，同比下 | | | 降 442.96 ...

编号：2025-001 投资者关系活动 类别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： 参与单位名称 及人员 东兴证券 任天辉 林松 牛淑娜 时间 2025 年 4 月 23 日 10:00-12:00 地点 公司证券投资部办公室 公司接待人员 姓名 副 总 经 理 、 董 事 会 秘 书 王海斌先生 证 券 事 务 代 表 张峰先生 投资者关系活动 主要内容介绍 1.请问公司产品螺杆钻具的主要功能有那些，是否有新产品研发？ 答：公司主要产品螺杆钻具主要功能是为钻头提供钻进动力，主要应 用于石油、天然气、页岩气、煤层气、地热能的钻井作业开采，在钻 井过程中可以用于定向钻井，水平钻井，广泛应用于国内外陆地和海 洋油田钻井工程中，目前公司新开发了旋转导向专用螺杆钻具、近钻 头螺杆钻具、超高温螺杆钻具、高造斜螺杆钻具等产品，公司为满足 客户的需求不断的开发出新产品。 2. 请问公司产品是否生产水力振荡器，他的主要功能有那些？ 答：公司目前有水力振荡器的生产，他与螺杆钻具属于一个系列，他 的作用主要是为了解决水平钻井过程中的托压问题，减少钻具对于 ...

江苏凯伦建材股份有限公司投资者关系活动记录表 问题三、请介绍下公司本次收购标的公司业绩承诺等情况 公司本次收购事项，标的公司股东苏州矽彩光电科技有限公司、实际控制人陈显锋 承诺：标的公司 2025 年度、2026 年度、2027 年度实现净利润分别不低于 5,500.00 万元、 7,500.00 万元、11,000.00 万元，即累积实现的净利润为 24,000 万元。 问题四、请介绍下公司本次收购标的公司后的公司治理情况 等交割完成后，标的公司将设董事会，董事会由 3 人组成，2 名由公司委派，1 名 由其他股东委派；在标的公司应当设置职工董事的情况下，董事会由 5 人组成，3 名由 公司委派；董事长为目标公司法定代表人，由其他股东委派的董事担任；标的公司不设 监事会、不设监事。 标的公司实行董事会领导下的总经理负责制，在业绩承诺期间，在标的公司董事会 的授权下总经理拥有日常经营决策管理权，并保证管理团队在业绩承诺期内稳定。 标的公司总经理由董事长提名，董事会聘任。公司委派的董事按照目标公司章程行 使权利、履行义务。 标的公司设财务总监（财务负责人），由公司推荐人选，董事会聘任，标的公司管 理层应充分保证 ...

Group 1: Financial Performance - In 2024, the company achieved a revenue of 770 million RMB, a year-on-year increase of 2.9% [2] - Q1 2025 revenue reached 197 million RMB, growing by 2.6% year-on-year [2] - The gross profit margin for 2024 was 58.6%, up by 1 percentage point year-on-year; Q1 2025 gross profit margin was 58.4%, an increase of 0.4 percentage points [2] - The net profit attributable to shareholders for 2024 was 176.79 million RMB, a 12.2% increase year-on-year; Q1 2025 net profit was 47.15 million RMB, growing by 11.7% [2] - The net profit margin for 2024 was 23.0%, up by 1.9 percentage points year-on-year; Q1 2025 net profit margin was 23.9%, also an increase of 1.9 percentage points [2] Group 2: Expense Analysis - In 2024, total sales expenses were 141.01 million RMB, down by 4.4% year-on-year; Q1 2025 sales expenses were 33.94 million RMB, decreasing by 5.4% [3] - Management expenses for 2024 totaled 85.75 million RMB, an increase of 8.8% year-on-year; Q1 2025 management expenses were 18.79 million RMB, down by 20.5% [3] - R&D expenses in 2024 amounted to 34.99 million RMB, up by 25.0% year-on-year; Q1 2025 R&D expenses were 9.53 million RMB, increasing by 37.5% [3] Group 3: Market Trends and Product Performance - The lens industry is experiencing a shift towards high-end products, with a notable growth in demand for advanced products due to consumer upgrades and domestic replacements [3] - The company's lens business grew by 8.72% year-on-year, excluding the negative impacts from overseas and raw material businesses [3] - The PMC Ultra Bright series saw a revenue increase of nearly 45.6% in 2024, with three star products accounting for 54.6% of regular lens revenue [3] - The "Easy Control" series for myopia management achieved sales of 41.58 million RMB in Q4 2024, a year-on-year growth of 23.6% [3] Group 4: Strategic Initiatives - The company has permanently exited price wars since 2019, which has garnered goodwill from channels and customers [6][7] - A new product, the Easy Control Pro2.0, was launched, which is believed to have superior control effects compared to previous models [8] - The company is focusing on customer development, particularly in the medical field, and has initiated a seed customer program to support key clients [8] - A new marketing strategy was announced with the endorsement of a new spokesperson, emphasizing the importance of the "Easy Control" product line [9] Group 5: Future Outlook - The penetration rate for defocus lenses is currently around 7% to 8%, with a significant growth potential as over 120 million children in China require them [5] - The company anticipates sustained growth in the defocus lens market despite recent price competition, as external pressures have begun to ease [6] - The company is also exploring the smart glasses market, focusing on providing complete solutions and addressing challenges in fitting and service [10][11]